Brain plaques are clumps of a sticky protein fragment called amyloid-beta that accumulate between nerve cells in the brain, and they are most closely associated with Alzheimer’s disease. These deposits can begin forming years or even decades before a person notices any cognitive problems, which makes them one of the earliest detectable markers of Alzheimer’s pathology. But the relationship between plaques and actual symptoms is more complicated than it first appears, and the science around treating them has shifted dramatically in just the past few years.
How Brain Plaques Form
Amyloid-beta is a small protein fragment that is produced naturally in the brain as a byproduct of normal cellular activity. A larger molecule called amyloid precursor protein sits in the membranes of nerve cells, and enzymes routinely snip it into smaller pieces. Most of those fragments are cleared away without incident. The problem starts when certain versions of amyloid-beta, particularly longer forms known as Aβ42 and Aβ40, are produced in excess or not cleared efficiently. These fragments are prone to sticking together. First they form small clusters called soluble oligomers, which are highly toxic to nearby neurons. Over time, these oligomers aggregate further into the dense, fibrous deposits that show up on brain scans as plaques.1PubMed Central. Spatial memory deficits in Alzheimer’s disease and their connection to cognitive maps’ formation by place cells and grid cells
The process is gradual. A person’s brain can harbor growing plaque deposits for fifteen to twenty years before symptoms emerge. This long silent phase is why researchers have focused so heavily on finding ways to detect and intervene against plaques early, before irreversible damage is done.
The APOE4 Gene and Other Risk Factors
The single strongest genetic risk factor for the common late-onset form of Alzheimer’s is a variant of the APOE gene called APOE4. Everyone carries two copies of APOE, and the gene comes in three common versions: ε2, ε3, and ε4. Carrying even one copy of the ε4 variant is linked to earlier and more extensive formation of amyloid plaques.2PubMed Central. Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies People with two copies face a substantially higher lifetime risk of developing Alzheimer’s than those with zero.
APOE4 does not cause Alzheimer’s on its own. Plenty of carriers never develop dementia, and plenty of people without the variant do. But APOE4 appears to impair the brain’s ability to clear amyloid-beta efficiently, which tips the balance toward accumulation. The protein produced by APOE4 is less effective at binding and transporting lipids and amyloid fragments compared to the more common ε3 version, which may partly explain why plaques build up faster in carriers.
Beyond genetics, age is the biggest risk factor. The brain’s waste-clearance systems slow with age, and the balance between amyloid production and removal shifts. Other contributors include cardiovascular disease, diabetes, chronic sleep deprivation, head injuries, and prolonged physical inactivity. Many of these overlap with known risk factors for vascular disease, which has led researchers to view brain health and heart health as deeply intertwined.
What Plaques Do to the Brain
Amyloid plaques do not simply sit inertly in the brain. They trigger a cascade of damaging events. One of the most important is neuroinflammation: the brain’s immune cells, called microglia, recognize plaques as foreign material and mount an inflammatory response. In theory, this response should help clear the debris. In practice, chronic activation of microglia creates a vicious cycle. The inflammation damages nearby neurons, which releases more cellular debris, which provokes more inflammation. Amyloid aggregation and neuroinflammation form a feed-forward loop that worsens synaptic loss and neuronal death over time.3PubMed Central. Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions
Plaques also appear to accelerate the spread of tau, a different protein that forms tangles inside neurons. The relationship between amyloid and tau is one of the thorniest questions in Alzheimer’s research. Current thinking holds that amyloid accumulation sets the stage, and tau pathology drives much of the actual cell death and cognitive decline. This helps explain a puzzling observation: some older adults have significant amyloid plaque deposits at autopsy yet showed no signs of dementia during life. Their brains may have resisted the downstream tau pathology, or they may have had enough cognitive reserve to compensate. Either way, plaques alone do not guarantee symptoms, which is an important caveat when interpreting a positive amyloid scan.
Symptoms Linked to Plaque Buildup
Because plaques tend to accumulate first in brain regions involved in memory encoding and spatial navigation, the earliest symptoms of plaque-driven Alzheimer’s disease are usually subtle memory lapses. A person might repeatedly forget recent conversations, misplace objects in unusual places, or struggle to recall the name of someone they met last week. These early signs are often dismissed as normal aging, which is part of why diagnosis frequently comes late.
Spatial memory problems are another hallmark. Getting lost in familiar environments, difficulty following directions, or trouble judging distances can appear early in the disease process. Research has linked these deficits to amyloid-related disruption of place cells and grid cells, specialized neurons in the hippocampus and entorhinal cortex that help the brain build internal maps of the environment.1PubMed Central. Spatial memory deficits in Alzheimer’s disease and their connection to cognitive maps’ formation by place cells and grid cells As the disease progresses, symptoms broaden to include difficulty with language, planning, decision-making, and eventually basic self-care.
A distinction worth making: the mild forgetfulness that many people experience with age is not the same thing as Alzheimer’s. Occasionally forgetting where you parked your car is qualitatively different from forgetting that you own a car. The difference lies partly in whether the memory deficit is progressive and whether it interferes with daily functioning. Clinicians use structured cognitive tests to distinguish the two, but the line is not always obvious in the earliest stages.
How Doctors Detect Plaques
For decades, amyloid plaques could only be confirmed at autopsy. That changed with two technologies: amyloid PET imaging and cerebrospinal fluid biomarkers. Both allow doctors to detect amyloid pathology in living patients, and they have fundamentally reshaped Alzheimer’s diagnosis. These tools can identify amyloid changes even at the preclinical stage or during mild cognitive impairment, well before full-blown dementia develops.4Alzheimer’s & Dementia. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer’s disease
An amyloid PET scan uses a radioactive tracer that binds to amyloid deposits. The scan lights up regions where plaques have accumulated, giving doctors a visual map of the amyloid burden. Cerebrospinal fluid tests measure concentrations of specific amyloid fragments; a drop in Aβ42 in the spinal fluid, paradoxically, signals that the protein is getting trapped in brain plaques rather than flowing freely. Blood-based biomarkers are also emerging and may eventually make screening far more accessible, though they are not yet standard in routine clinical practice.
Detection matters because it changes treatment options. The new anti-amyloid antibody drugs approved in recent years require confirmation of amyloid pathology before a patient can start treatment. Without a positive amyloid PET scan or corresponding biomarker results, the drugs will not be prescribed. So for people worried about cognitive decline, getting tested for amyloid is no longer just an academic exercise; it directly determines what therapies are available.
Anti-Amyloid Antibody Treatments
The treatment landscape for brain plaques has changed more in the past five years than in the previous three decades. After a long string of failed clinical trials targeting amyloid, two monoclonal antibodies have now received approval from the U.S. Food and Drug Administration: aducanumab (Aduhelm) and lecanemab (Leqembi), with donanemab expected to follow. These drugs are infused intravenously and work by binding to amyloid deposits and flagging them for removal by the brain’s immune cells.
Lecanemab has the strongest clinical evidence so far. In its large pivotal trial, roughly four out of five patients receiving lecanemab achieved amyloid-negative PET scans, meaning their plaque burden dropped below the threshold for a positive reading. The drug also slowed cognitive decline by about 27% compared to placebo on a composite cognitive scale.5PubMed Central. A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer’s Disease Whether that degree of slowing is clinically meaningful for individual patients remains debated among neurologists. A 27% reduction in the rate of decline, spread over eighteen months, translates to a modest difference in day-to-day functioning. Some patients and families find it significant; others feel the benefit is too small relative to the cost, inconvenience, and risks.
The most concerning risk is amyloid-related imaging abnormalities, known by the acronym ARIA. These are brain swelling events or microbleeds that show up on MRI scans during treatment. Most ARIA episodes are mild and resolve on their own, but in rare cases they can cause serious neurological symptoms. APOE4 carriers face a higher risk of ARIA, which creates a difficult tradeoff: the patients at greatest genetic risk for Alzheimer’s are also at greatest risk of side effects from the drugs designed to treat it. Regular MRI monitoring is required during the treatment course.
Experimental Approaches Beyond Antibodies
Antibodies are not the only strategy being explored. One promising research direction involves gamma-secretase modulators, compounds that do not block amyloid production entirely but instead shift the enzyme that cuts amyloid precursor protein so that it produces shorter, less harmful amyloid fragments instead of the sticky Aβ42 form. In animal studies, one such compound reduced the formation and growth of new plaques and, unusually, also shrank existing plaques, an effect not typically seen with drugs that simply block amyloid production. The drug lowered levels of the harmful Aβ40 and Aβ42 fragments in brain fluid while increasing levels of shorter, benign fragments like Aβ37.6PubMed Central / Elsevier. γ-Secretase modulation inhibits amyloid plaque formation and growth and stimulates plaque regression in amyloid precursor protein/presenilin-1 mice
This approach is appealing because earlier attempts to shut down gamma-secretase entirely caused severe side effects, since the enzyme also processes other important proteins in the body. Modulating it rather than blocking it may sidestep those problems, though this has yet to be proven in humans. Other experimental strategies include anti-tau therapies, neuroinflammation-targeted drugs, gene therapies aimed at converting APOE4 to the less risky APOE3 form, and even focused ultrasound techniques that temporarily open the blood-brain barrier to improve drug delivery or amyloid clearance.
The broader trajectory in the field is toward combination approaches. Just as cancer treatment improved when clinicians stopped relying on a single drug and began targeting multiple pathways simultaneously, Alzheimer’s researchers increasingly suspect that treating amyloid alone will not be enough. Addressing inflammation, tau, and metabolic dysfunction alongside amyloid may ultimately prove necessary to meaningfully slow the disease.
Exercise, Sleep, and the Brain’s Cleanup System
One of the more fascinating discoveries in recent neuroscience is the glymphatic system, a network of channels that flushes waste products out of the brain. The system operates primarily during deep sleep, when cerebrospinal fluid flows through spaces around blood vessels and carries away metabolic waste, including amyloid-beta. When this system works well, amyloid fragments are cleared before they can aggregate. When it is impaired by poor sleep, aging, or other factors, waste accumulates.
Physical exercise appears to enhance glymphatic clearance. Animal studies have shown that regular exercise accelerates the flow of fluid through these channels, improves the function of astrocytes (the brain cells that help regulate the system), and reduces amyloid accumulation and neuroinflammation. Exercised animals in these studies were protected against synaptic dysfunction and cognitive decline compared to sedentary controls.7PubMed Central. The newly discovered glymphatic system: the missing link between physical exercise and brain health?
The connection between exercise, sleep, and brain waste clearance may form a reinforcing loop. Exercise improves sleep quality, and sleep is when glymphatic clearance is most active. Researchers have proposed that exercise’s well-documented benefits for brain health may partly operate through this glymphatic pathway.7PubMed Central. The newly discovered glymphatic system: the missing link between physical exercise and brain health? While much of the evidence comes from animal models and the human data is still catching up, the practical implication is straightforward: regular physical activity and consistent, high-quality sleep are two of the most accessible tools for supporting the brain’s natural defenses against plaque buildup. Neither is a guarantee against Alzheimer’s, but given the low risk and broad benefits, they remain the closest thing to a prevention strategy that the evidence currently supports.
When Plaques Are Found but Symptoms Are Not
As amyloid PET scans become more widely available, a growing number of older adults are learning they have significant plaque deposits despite feeling cognitively fine. This situation, sometimes called preclinical Alzheimer’s disease in research settings, raises difficult questions that medicine is still working through. Roughly a quarter to a third of cognitively normal older adults test positive for brain amyloid on PET scans. Not all of them will go on to develop dementia. Some will remain sharp for years or even the rest of their lives.
Why some brains tolerate plaques better than others is an active area of investigation. Part of the answer likely involves cognitive reserve, the idea that years of education, intellectually stimulating work, and social engagement build up a buffer that allows the brain to function well even as pathology accumulates. Part of it involves the degree to which tau pathology and inflammation have spread. And part may simply be genetic luck in how an individual’s immune system responds to amyloid deposits.
For the person sitting across from a neurologist who has just told them their scan is positive but their cognition is normal, the situation is unsettling. Current guidelines do not recommend starting anti-amyloid drugs for people without symptoms, though clinical trials are actively testing whether early intervention in this preclinical window could delay or prevent the onset of dementia. The results of those trials, expected over the next several years, may reshape how the entire field thinks about when and whether to treat brain plaques.